Dynamic Advisors Solutions LLC Purchases Shares of 3,375 Amgen, Inc. (AMGN)

Dynamic Advisors Solutions LLC purchased a new position in shares of Amgen, Inc. (NASDAQ:AMGN) in the fourth quarter, Holdings Channel reports. The firm purchased 3,375 shares of the medical research company’s stock, valued at approximately $587,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. FMR LLC increased its position in shares of Amgen by 4.8% during the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after purchasing an additional 2,587,041 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Amgen by 0.9% during the second quarter. Vanguard Group Inc. now owns 52,146,935 shares of the medical research company’s stock worth $8,981,266,000 after purchasing an additional 489,720 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Amgen by 1.7% during the third quarter. Bank of New York Mellon Corp now owns 8,166,002 shares of the medical research company’s stock worth $1,522,551,000 after purchasing an additional 140,117 shares in the last quarter. Nordea Investment Management AB increased its position in shares of Amgen by 12.9% during the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock worth $1,212,602,000 after purchasing an additional 806,119 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in shares of Amgen by 3.1% during the second quarter. The Manufacturers Life Insurance Company now owns 3,968,892 shares of the medical research company’s stock worth $683,562,000 after purchasing an additional 121,202 shares in the last quarter. 79.53% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

In related news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $185.62, for a total value of $283,070.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders sold a total of 4,575 shares of company stock worth $838,064 in the last 90 days. 0.19% of the stock is currently owned by insiders.

A number of analysts have recently commented on AMGN shares. Oppenheimer set a $205.00 target price on Amgen and gave the stock a “buy” rating in a research report on Tuesday, December 12th. Goldman Sachs cut Amgen from a “conviction-buy” rating to a “buy” rating in a research report on Friday, December 15th. Citigroup cut Amgen to a “neutral” rating in a research report on Monday, December 18th. Mizuho set a $192.00 target price on Amgen and gave the stock a “buy” rating in a research report on Friday, December 22nd. Finally, Piper Jaffray reiterated a “buy” rating on shares of Amgen in a research report on Tuesday, January 2nd. Two analysts have rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the stock. Amgen presently has an average rating of “Hold” and an average target price of $190.57.

Shares of AMGN stock opened at $168.14 on Friday. The stock has a market capitalization of $125,031.95, a P/E ratio of 13.37, a P/E/G ratio of 2.13 and a beta of 1.36. Amgen, Inc. has a 52-week low of $152.16 and a 52-week high of $201.23. The company has a debt-to-equity ratio of 1.35, a quick ratio of 5.17 and a current ratio of 5.49.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.03 by ($0.14). The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. The business’s revenue was down 2.7% on a year-over-year basis. During the same quarter last year, the firm earned $2.89 EPS. equities research analysts forecast that Amgen, Inc. will post 13.25 EPS for the current fiscal year.

Amgen announced that its Board of Directors has authorized a share buyback plan on Thursday, February 1st that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s management believes its shares are undervalued.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be given a $1.32 dividend. This represents a $5.28 annualized dividend and a yield of 3.14%. The ex-dividend date of this dividend is Wednesday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 41.97%.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/dynamic-advisors-solutions-llc-purchases-shares-of-3375-amgen-inc-amgn.html.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply